Keros Therapeutics, Inc. (KROS)

USD 17.13

(-4.83%)

Market Cap (In USD)

693.89 Million

Revenue (In USD)

151 Thousand

Net Income (In USD)

-152.99 Million

Avg. Volume

363.28 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
15.67-73.0
PE
-
EPS
-
Beta Value
1.236
ISIN
US4923271013
CUSIP
492327101
CIK
1664710
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Jasbir S. Seehra Ph.D.
Employee Count
-
Website
https://www.kerostx.com
Ipo Date
2020-04-08
Details
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.